Related Experiment Video
Updated: Jun 12, 2025
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and
1Dana-Farber Cancer Institute.
Background:
Patients diagnosed with glioblastoma multiforme (GBM) often undergo concurrent temozolomide and radiation therapy. Antineoplastic medication nonadherence continues to be an issue for patients with cancer.
Objectives:
This quality improvement project aimed to institute an evidence-based standardized educational tool for patients with GBM undergoing concurrent temozolomide and radiation therapy.
Methods:
To assess medication adherence, patients completed the Brief Adherence Rating Scale at the end of the last radiation therapy visit. Patients and providers completed satisfaction surveys.
Findings:
Data analysis from the administered Brief Adherence Rating Scale demonstrated a mean of 99.3% (N = 13) medication adherence among participants. Median medication adherence was demonstrated to be 100%, with scores ranging from 93% to 100%.
